(Q36045493)

11 August 2017

1 reference

title

Predictors and markers of clozapine response (English)

1 reference

11 August 2017

2

Gary Remington

1 reference

11 August 2017

Carmen Chung

1

1 reference

11 August 2017

language of work or name

1 reference

17 February 2005

1 reference

11 August 2017

number of pages

19

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

11 August 2017

volume

179

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

317-335

1 reference

The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Paroxysmal EEG Activity and Psychopathology During the Treatment with Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-005-2174-X

Clozapine: a comparison with other novel antipsychotics

21 January 2018

1 reference

12 December 2020

Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations

1 reference

12 December 2020

Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine

1 reference

12 December 2020

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.

1 reference

12 December 2020

Clozapine induced increase of human plasma norepinephrine

1 reference

12 December 2020

An association study of the neurotensin receptor gene with schizophrenia and clozapine response.

1 reference

12 December 2020

Double-blind study of clozapine dose response in chronic schizophrenia

1 reference

12 December 2020

The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia

1 reference

12 December 2020

Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.

1 reference

12 December 2020

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia

1 reference

12 December 2020

The brain metabolic patterns of clozapine- and fluphenazine-treated female patients with schizophrenia: evidence of a sex effect

1 reference

12 December 2020

The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study.

1 reference

12 December 2020

Clozapine response and plasma catecholamines and their metabolites

1 reference

12 December 2020

1 reference

12 December 2020

Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response.

1 reference

12 December 2020

Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.

1 reference

12 December 2020

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

1 reference

12 December 2020

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

1 reference

12 December 2020

Normalization of information processing deficits in schizophrenia with clozapine

1 reference

12 December 2020

EEG abnormalities during treatment with typical and atypical antipsychotics

1 reference

12 December 2020

Cytochrome P450 and therapeutic drug monitoring with respect to clozapine

1 reference

12 December 2020

Effects of Clozapine on Plasma Catecholamines and Relation to Treatment Response in Schizophrenia: A Within-Subject Comparison with Haloperidol

1 reference

12 December 2020

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

1 reference

12 December 2020

Early response to clozapine in schizophrenia

1 reference

12 December 2020

Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network

1 reference

12 December 2020

Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.

1 reference

12 December 2020

Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia

1 reference

12 December 2020

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

1 reference

12 December 2020

Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients

1 reference

12 December 2020

EEG alterations in patients treated with clozapine in relation to plasma levels

1 reference

12 December 2020

The Suffolk County Mental Health Project: demographic, pre-morbid and clinical correlates of 6-month outcome.

1 reference

12 December 2020

Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia.

1 reference

12 December 2020

Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia

1 reference

12 December 2020

The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes

1 reference

12 December 2020

EEG abnormalities before clozapine therapy predict a good clinical response to clozapine.

1 reference

12 December 2020

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor.

1 reference

12 December 2020

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

1 reference

12 December 2020

Auditory event-related potential indices of fronto-temporal information processing in schizophrenia syndromes: valid outcome prediction of clozapine therapy in a three-year follow-up.

1 reference

12 December 2020

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

1 reference

12 December 2020

Effects of clozapine on cognitive function in schizophrenia

1 reference

12 December 2020

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1 reference

12 December 2020

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

12 December 2020

Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings

1 reference

12 December 2020

Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients.

1 reference

12 December 2020

Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine

1 reference

12 December 2020

Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment

1 reference

12 December 2020

Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)).

1 reference

12 December 2020

Clozapine-induced electroencephalogram changes as a function of clozapine serum levels

1 reference

12 December 2020

Basic symptoms and P300 abnormalities in young schizophrenic patients

1 reference

12 December 2020

Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication

1 reference

12 December 2020

Genetic variation of the 5-HT2A receptor and response to clozapine

1 reference

12 December 2020

Clozapine: neuropsychological and neuroimaging studies

1 reference

12 December 2020

High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients

1 reference

12 December 2020

Premorbid adjustment as predictor of outcome in schizophrenia: results of a prospective study

1 reference

12 December 2020

Clozapine--pharmacokinetic investigations and biochemical effects in man.

1 reference

12 December 2020

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

1 reference

12 December 2020

Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.

1 reference

12 December 2020

Discriminant cognitive factors in responder and non-responder patients with schizophrenia

1 reference

12 December 2020

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

1 reference

12 December 2020

Cerebral morphometry and clozapine treatment in schizophrenia

1 reference

12 December 2020

Predictors of response to clozapine therapy.

1 reference

12 December 2020

EEG abnormalities associated with clozapine treatment

1 reference

12 December 2020

Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking

1 reference

12 December 2020

Effect of Clozapine on Apomorphine-Induced Growth Hormone Secretion and Serum Prolactin Concentrations in Schizophrenia

1 reference

12 December 2020

Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

12 December 2020

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

12 December 2020

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

1 reference

12 December 2020

P300 and symptom improvement in schizophrenia

1 reference

12 December 2020

Cognitive effects and antipsychotic treatment.

1 reference

12 December 2020

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

1 reference

12 December 2020

IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol

1 reference

12 December 2020

Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response

1 reference

12 December 2020

Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications

1 reference

12 December 2020

Association between clozapine response and allelic variation in the 5-HT2C receptor gene

1 reference

12 December 2020

Blood biogenic amines during clozapine treatment of early-onset schizophrenia.

1 reference

12 December 2020

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

1 reference

12 December 2020

A five-year longitudinal study of the regional cerebral metabolic changes of a schizophrenic patient from the first episode using Tc-99m HMPAO SPECT.

1 reference

12 December 2020

Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study

1 reference

12 December 2020

Serotonin function and treatment response to clozapine in schizophrenic patients

1 reference

12 December 2020

Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients

1 reference

12 December 2020

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.

1 reference

12 December 2020

Predictors of response to clozapine

1 reference

12 December 2020

Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia

1 reference

12 December 2020

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients

1 reference

12 December 2020

Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia

1 reference

12 December 2020

The effects of clozapine on cognitive functioning in schizophrenia

1 reference

12 December 2020

A clinical study of clozapine treatment and predictors of response in a Canadian sample

1 reference

12 December 2020

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1 reference

12 December 2020

Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study.

1 reference

12 December 2020

Clozapine-induced EEG abnormalities and clinical response to clozapine

1 reference

12 December 2020

Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.

1 reference

12 December 2020

Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine

1 reference

12 December 2020

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response

1 reference

12 December 2020

Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-IBZM SPECT study

1 reference

12 December 2020

Simultaneous observation of regional cerebral blood flow and event-related potential during performance of an auditory task.

1 reference

12 December 2020

D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine.

1 reference

12 December 2020

Quantified EEG changes associated with a positive clinical response to clozapine in schizophrenia

1 reference

12 December 2020

Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia.

1 reference

12 December 2020

The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics.

1 reference

12 December 2020

[Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence]

1 reference

12 December 2020

Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia

1 reference

12 December 2020

Response to clozapine in chronic psychotic patients

1 reference

12 December 2020

Ziprasidone, a new atypical antipsychotic drug

1 reference

12 December 2020

Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects

1 reference

12 December 2020

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

12 December 2020

Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

1 reference

12 December 2020

The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures

1 reference

12 December 2020

Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response

1 reference

12 December 2020

Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study

1 reference

12 December 2020

Gating of auditory P50 in schizophrenics: unique effects of clozapine

1 reference

12 December 2020

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

12 December 2020

[The P 300 potential in schizophrenia]

1 reference

12 December 2020

Prefrontal cortical sulcal widening associated with poor treatment response to clozapine

1 reference

12 December 2020

Predictors of clinical outcome in schizophrenic patients responding to clozapine

1 reference

12 December 2020

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

1 reference

12 December 2020

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

1 reference

12 December 2020

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

1 reference

12 December 2020

Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.

1 reference

12 December 2020

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

1 reference

12 December 2020

Premorbid adjustment and remission of positive symptoms in first-episode psychosis.

1 reference

12 December 2020

Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior

1 reference

12 December 2020

Clozapine response and the 5HT2C Cys23Ser polymorphism.

1 reference

12 December 2020

Association between regional brain volumes and clozapine response in schizophrenia

1 reference

12 December 2020

Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning

1 reference

12 December 2020

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

1 reference

12 December 2020

The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy

1 reference

12 December 2020

Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia.

1 reference

12 December 2020

Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval

1 reference

12 December 2020

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

1 reference

12 December 2020

Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia.

1 reference

12 December 2020

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

12 December 2020

Clozapine in severe mood disorders.

1 reference

12 December 2020

Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia

1 reference

12 December 2020

Predictors of clozapine response in schizophrenia

1 reference

12 December 2020

Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.

1 reference

12 December 2020

EEG abnormalities in clozapine-treated schizophrenic patients

1 reference

12 December 2020

Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors

1 reference

12 December 2020

Auditory event-related potentials in schizophrenia and depression.

1 reference

12 December 2020

Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

1 reference

12 December 2020

Can clozapine response be predicted? A naturalistic pilot study

1 reference

12 December 2020

Regional cortical anatomy and clozapine response in refractory schizophrenia

1 reference

12 December 2020

Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics

1 reference

12 December 2020

Clozapine effects on glucose metabolic rate in striatum and frontal cortex

1 reference

12 December 2020

Clozapine in China: a review and preview of US/PRC collaboration

1 reference

12 December 2020

Stability of neurological signs with clozapine treatment

1 reference

12 December 2020

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

Effects of clozapine on auditory event-related potentials in schizophrenia

1 reference

12 December 2020

10.1007/S00213-005-2174-X

Identifiers

DOI

1 reference

11 August 2017

1 reference